Josh (@JoshInProgress) header
Josh (@JoshInProgress) profile picture

Partner at @TrustPointe and Owner of @TareAPI. Chemist, Engineer, Corporate Veep. Interests include Finance, Science, Entrepreneurship. Views are my own.

Grand Rapids, MI
Joined August 2022
Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)Photo by Josh (@JoshInProgress)
Been talking about this for over two years now. Still there are Shitlab 206s out there representing TAMC / TYMC counts as sterility. When are researchers going to demand more from peptide vendors? Holy fuck I don’t even care if you hate me and use Vanguard, just use someone that can read.
Dustin out here writing bangers 💥 What he’s describing is method sensitivity USP <61> with a TAMC/TYMC result is specifically designed for nonsterile products (oral liquids, capsules, etc). It assumes large quantities of microbes present, and so the method isn’t designed to detect small amounts of microbes. So stop plating your freaking peptides and start USP <71>ing them
2
7
411
“PCR gives me a sterility test result the same day. I can’t believe I’m the only lab to figure this out! Those multi-billion dollar pharmaceutical companies are so stupid!”
1
2
5
95
Meanwhile researchers injecting peptides they tested: Why does my blood hurt? This peptide is not for me!
1
27
I’m going to go flip Magic the Gathering cards. TrustFlipe Card Trading LLC
2
3
324
Josh retweeted
“PCR gives me a sterility test result the same day. I can’t believe I’m the only lab to figure this out! Those multi-billion dollar pharmaceutical companies are so stupid!”
1
2
5
95
Josh retweeted
The best compliment we’ve gotten is, “I use your lab because I know if it passed your testing, it would pass any other lab it was sent to and protect my sales” Not “wow, thank you for having robust methods to protect my customers.” Try explaining to peptide vendors that you’re better than everyone else at finding problems with their product and watch how fast they lose your number. As researchers are fine with Shitlab 206, they will keep using them
1
1
7
124
Why we haven’t been able to get researchers to demand their peptide vendors use TrustPointe or Vanguard only is beyond me. Clearly other labs don’t know what the fuck they are doing. PCR and USP <61> for sterility? chromatography that that violates basic analytical chemistry practice? And researchers are like, “Oh yeah I get my peptides Xtra Freedom Peptides and their COAs from Shitlab 206 are great!” Boggles the mind. Enjoy your acinetobacter infection.
Apologies for the novel, but this is one that irritates me. A negative PCR ≠ a USP 71(or 73) passing sterility. There's a significant difference between detecting microbial DNA and demonstrating the absence of viable microbial contamination using a validated sterility procedure. USP <71> testing relies on microbial growth in 2 types of media over 14 days. PCR detects nucleic acid sequences. Depending on the assay, that DNA may originate from viable organisms, dead organisms, or residual microbial material. A negative PCR result also does not establish that viable contamination is absent, particularly when the organism concentration is below the PCR detection limit. It's more than a theoretical concern, or semantics. Broad-range 16S PCR for sterility screening reported detection sensitivities ranging from 10 to 100 CFU/mL. Thats substantial when evaluating products where contamination may consist of only a few viable organisms. Another important distinction is that 16S PCR primarily detects bacteria. It does not adequately address fungal contamination. Adding a fungal PCR assay improves coverage, but it does not automatically establish equivalence to USP <71>. Much of the failed USP 71 sterility tests of RUO I also reviewed and frequently used commercial PCR systems. Sartorius, one of the major manufacturers in this field, has published studies demonstrating favorable comparisons between its Microsart PCR assays and traditional compendial methods. However, Sartorius explicitly states in its own technical documentation that its Microsart ATMP system is not a replacement for classical USP <71> sterility testing. It's good for a screen for products manufactured in highly controlled and regulated cGMP environments. I often used it to quickly screen raw materials and finished productstopical formulations. I would never rely on it for products where nothing concerning the manufacturing can be confirmed, or where the product would be injected. There is a difference between demonstrating comparable analytical performance in a limited study and validating a method as a replacement for compendial sterility testing across different pharmaceutical formulations. A 2019 study published in the Journal of Clinical Microbiology evaluated 118 microbial isolates using traditional USP <71> and alternative automated culture systems. One alternative system detected only 71.2% of the organisms after extended incubation. Validated USP 71 methods do exist. At @Vanguard_Lab , we offer traditional USP <71> sterility testing as well as rapid sterility testing using the Charles River Celsis ATP bioluminescence system, validated as an alternative to USP <71>. To put in perspective, we paid over 100K for the instrument and nearly another 100k on validation and method suitability studies of more than 50 different peptides at different mgs, different filler materials, and different combinations of peptides. Celsis uses microbial growth followed by ATP-based detection, allowing a shortened incubation period while retaining a growth-based approach to detecting viable contamination. We also participate in independent, third-party Pharma ISO accredited proficiency testing with our traditional USP <71> and USP <71>-equivalent rapid sterility methods That provides an additional external assessment of laboratory performance beyond our internal quality controls and method validation. USP also specifically addresses certain rapid sterility technologies under chapters <72> and <73>, including respiration-based detection and ATP bioluminescence for applicable short-life products. PCR is not inherently excluded from alternative-method validation. USP <1223> provides a framework for evaluating alternative microbiological technologies. However, I have not found evidence that a commercially available standalone PCR kit is universally recognized by USP as a direct replacement for USP <71>, Nor have I seen any evidence that anyone in this space using PCR is doing method suitability on PC methods or participating in proficiency testing. If a laboratory is advertising PCR screen as a USP <71> sterility test, I would ask to see the validation demonstrating that equivalence, including low-level microbial recovery, bacterial and fungal coverage, product-specific suitability, assay inhibition, and detection probability at very low contamination levels. I would also want to know whether that laboratory participates in independent proficiency testing for the methodology being offered. We use molecular methods at Vanguard, and consider PCR an extremely valuable tool for pathogen detection and identification. We use it daily in our food and pharma departments. It can also be useful for rapid preliminary screening but screening and compendial sterility testing are not interchangeable. There is nothing wrong with offering PCR microbial screening. There is a problem with advertising that screening as USP <71> sterility testing without the necessary supporting validation. If someone wants us to provide a rapid PCR or other rapid micro method we are happy to do so, but we will not list it on our COA as USP 71, or sterility. The distinction matters scientifically, analytically, and from a regulatory standpoint.
8
2
20
1,202
Any lab that represented PCR or USP <61> as sterility lacks the critical thinking skill necessary to do anything accurately, and more importantly, safely in this space. I not a fucking microbiologist but I can read and I know USP <71> is the sterility gold standard all methods are judged against. What else don’t they understand about what they are doing? Do they understand the concept of coelution and control for it during method design?
2
4
123
Until you researchers start demanding better, peptide vendors are going to use the cheapest, shittiest lab they can find. They are incentivized to maximize profit, and many of them will do it at your expense if you let them.
2
1
4
88
Wage slave by day. Method validation reviewer by night.
4
275
Replying to @Polymarket
You’d think this would be a job for American troops but here we are
5
3
99
5,067
Only one I trust He was on the “PCR sterility is bullshit” bandwagon long before anyone here noticed Cares about what the tests mean and that they’re validated
7
2
31
3,319
Every measurement is only an approximation of the true value Some approximations are better than others. Tape measure vs. digital calipers
2
4
265
Nintendo lawyers are drafting the lawsuit now
116
Never met a male Chinese salesperson on Alibaba 🤔
3
4
417
That was a pretty sturdy takedown haha
1
3
62
Dustin out here writing bangers 💥 What he’s describing is method sensitivity USP <61> with a TAMC/TYMC result is specifically designed for nonsterile products (oral liquids, capsules, etc). It assumes large quantities of microbes present, and so the method isn’t designed to detect small amounts of microbes. So stop plating your freaking peptides and start USP <71>ing them
Replying to @JoshInProgress
We get this request all the time. Most of the time I can explain why USP <61>/bioburden testing is not appropriate as a substitute for sterility testing on finished injectables. If a client insists, we'll do it, with the limitations clearly explained. USP <61> is a quantitative method for nonsterile products. It has legitimate applications for monitoring bioburden during sterile manufacturing, but it does not establish finished-product sterility. With a typical 1:10 dilution and 1 mL plated, no colonies means we report <10 CFU/mL, not zero, not "non-detect," not "no growth," and not "passed sterility." The actual reporting limit depends on the dilution and volume tested. We report TAMC and TYMC with the appropriate reporting limits. We have multiple microbial enumeration methods on our ISO accreditation scope, and accurately reporting results relative to the dilution factor and method reporting limit is non-negotiable. There could still be viable contamination below that reporting limit. For perspective, under USP <1111>, an oral capsule has acceptance criteria of 1,000 CFU/g for TAMC and 100 CFU/g for TYMC. A result of <10 CFU/g is below both enumeration limitst. That makes sense for a nonsterile oral dosage form. Now consider an injectable. A USP <61> result of <10 CFU/mL could still represent a contaminated product that would fail USP <71>. USP <71> doesn't have a permissible microbial count. It is a qualitative sterility test. Evidence of microbial growth means the product does not comply. I'm amazed at how often I see COAs where a negative USP <61> result is presented as evidence of sterility. It tells me either the laboratory doesn't understand the limitations of its own methodology, or the results are being presented in a way that makes them appear to establish something they don't. We'll perform the testing a client requests when appropriate, but we're not going to misrepresent what the results establish.
1
1
7
887